Japan 2010s In Review: Specialize, Focus, Innovate
Decade Marked By M&A, Restructuring, Positive Regulations
Executive Summary
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
You may also be interested in...
Ranbaxy Brothers Arrested, Downward Spiral Intensifies
The Singh brothers of Ranbaxy have been arrested over allegations of financial fraud and things appear headed further downhill. Daiichi Sankyo is also separately pursuing enforcement of damages against the brothers.
PMDA Chief Defends Japan Spinal Cord Therapy Approval
The head of Japan’s drug and device regulator has defended and supported the country’s recent world-first decision to grant approval to a novel cell-based therapy for spinal cord injuries, saying that patient considerations came first.
Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.